XNAS · Healthcare · Biotechnology
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.27 | -0.13 | +51.85% | $4.6M | ✅ Beat | +0.00% | -7.97% | — |
| 2026-03-10 | Q4 2025 | -0.24 | -0.20 | +16.67% | $5.6M | ✅ Beat | -2.27% | -4.72% | +22.22% |
| 2025-11-12 |
| Q3 2025 |
| -0.35 |
| -0.26 |
| +25.71% |
| $6.5M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-14 | Q2 2025 | -0.44 | -0.41 | +6.82% | $0 | ✅ Beat | +1.43% | +16.40% | +19.58% |
| 2025-03-10 | Q4 2024 | -0.47 | -0.37 | +21.28% | $4.0M | ✅ Beat | -1.34% | +12.67% | -0.79% |
| 2024-11-06 | Q3 2024 | -0.47 | -0.43 | +8.51% | $3.0M | ✅ Beat | -3.79% | -19.70% | -27.71% |
| 2024-08-12 | Q2 2024 | -0.42 | -0.46 | -9.52% | $0 | ❌ Miss | +30.53% | +23.58% | +5.26% |
| 2024-05-07 | Q1 2024 | -0.48 | -0.42 | +12.50% | $0 | ✅ Beat | -2.97% | +4.32% | +2.16% |
Showing last 8 quarters.